# # Exscientia Case Study 

## Overview and Origin

* Company Name: Exscientia 

* Incorporated in 2012 

* Founded by Andrew Hopkins

* The idea came about when Andrew was a PhD student in the 1990's researching HIV drugs and thought of how much more efficient it owuld be of there was technology to automate the testing and discovery of new molecules that can be combined into pharmaceutical drugs 

* Esxcientia went public on October 1, 2021 on the NASDAQ stock exchange under the ticker symbole EXAI, having rasied over 672.7 million. They have a current market cap of 770.88 million with an enterprise value of 328.35 million

## Business Activities

* Exscientia is working to reduce the time it takes to discover, design and develope new pharmacautical drugs. They also incorporate target identification and patient selection based on DNA samples to provide drug therapies to patients. 

* Who is the company's intended customer? Is there any information about the market size of this set of customers?

* What solution does this company offer that their competitors do not or cannot offer? (What is the unfair advantage they utilize?)

* Which technologies are they currently using, and how are they implementing them? (This may take a little bit of sleuthing&mdash;you may want to search the companyâ€™s engineering blog or use sites like Stackshare to find this information.)

## Landscape

* Exscientia is in the medical/healthcare and are considered a biotech company 

* What have been the major trends and innovations of this field over the last 5&ndash;10 years?

* What are the other major companies in this field?

## Results

* What has been the business impact of this company so far?

* One of the core metrics used by companies in this field is getting their drugs to clinical trials. Exscientia was the first AI drug company to get three drugs to trial. 

* How is your company performing relative to competitors in the same field?

## Recommendations

* I would advise this company to add blood and saliva tests that can be offered in doctors offices or sent away for similar to gelealogy companies like 23AndMe. 

* Assuming permission is granted, this would significantly increase the data set that can be used for training their models as well as opening a new revenue stream. This would also increase the canidate pool for patient selection of new designer drugs.  

* Predictive analytics would useful here, measuring known genetic markers of disease against a patient's medical history. 

* Why are these technologies appropriate for your solution?

* Sources:
  https://www.labiotech.eu/trends-news/exscientia-drug-discovery-ai/#:~:text=Exscientia%27s%20total%20winnings%20from%20the,2.5B%20(%242.9B)
  https://stockanalysis.com/stocks/exai/
  https://www.cbinsights.com/company/exscientia
  
  
